Related Experiment Video
Updated: Oct 5, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Expanding the spectrum of Gorham Stout disease exploring a single center pediatric case series
I Rana1, P S Buonuomo1, G Mastrogiorgio1
1Rare Diseases and Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Insights
Gorham-Stout Disease (GSD) requires prompt diagnosis and multidisciplinary care to prevent severe complications. Early identification and treatment are crucial for managing this rare bone disorder.
Area of Science:
- Medicine
- Orthopedics
- Rare Diseases
Background:
- Gorham-Stout Disease (GSD), or vanishing bone disease, is an ultrarare condition causing progressive osteolysis and bone loss.
- GSD is characterized by intraosseous lymphatic vessel proliferation and affects all ages, predominantly children and young adults.
- Approximately 300 cases of GSD have been documented globally.
Purpose of the Study:
- To retrospectively review internal patient data on Gorham-Stout Disease.
- To propose a diagnostic-therapeutic protocol for earlier GSD diagnosis and treatment.
- To enhance understanding of GSD management strategies.
Main Methods:
- Retrospective case-series review of internal patient datasets.
- Identification and analysis of pediatric Gorham-Stout Disease cases.
- Documentation of diagnostic and treatment pathways for GSD patients.
Main Results:
- Nine pediatric cases of Gorham-Stout Disease were identified and analyzed.
- Delayed diagnosis significantly correlated with increased patient morbidity.
- Multidisciplinary care was identified as essential for effective GSD management.
Conclusions:
- Early diagnosis of Gorham-Stout Disease is critical to mitigate morbidity.
- A multidisciplinary approach is paramount for optimal GSD patient management.
- Physicians must maintain awareness of GSD clinical features to prevent fatal outcomes from neglected cases.
Abstract:
Gorham-Stout Disease (GSD), also named vanishing bone disease, is an ultrarare condition characterized by progressive osteolysis with intraosseous lymphatic vessel proliferation and bone cortical loss. So far, about 300 cases have been reported. It may occur at any age but more commonly affects children and young adults. The aim of this study is to retrospectively review our internal patient series and to hypothesize a diagnostic-therapeutic protocol for earlier diagnosis and treatment. Clinical datasets from our center were examined to identify all GSD patients for collection and analysis. We identified 9 pediatric cases and performed a retrospective case-series review to examine and document both diagnosis and treatment. We found that delay in diagnosis after first symptoms played a critical role in determining morbidity and that multidisciplinary care is key for proper diagnosis and treatment. Our study provides additional insight to improve the critical challenge of early diagnosis and highlights a multidisciplinary treatment approach for the most appropriate management of patients with rare GSD disease. Although GSD is an ultrarare disease, physicians should keep in mind the main clinical features since neglected cases may result in potentially fatal complications.
More Related Videos
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...